Ship · Unlearn.AI
Streamlined QRL-201 randomized control trial efficiency via digital twins (Nov 2024 Summit
Streamlined QRL-201 randomized control trial efficiency via digital twins (Nov 2024 Summit
Unlearn.AI builds AI-generated 'digital twins' of clinical-trial patients, formally qualified by the EMA and reviewed positively by the FDA for reducing control-arm size in real trials.
This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.
Source
Published by Unlearn.AI on its own site — read the original case study on unlearn.ai ↗
Note: JS-rendered page, only nav/menu markup returned, no article body content extractable via WebFetch
More like this
Related use cases
- 01Partnered on ALS Digital Twin Group database for Phase 1/2 trial design
- 02Assessed digital twins for variance reduction/sample-size savings in Alzheimer's Phase 2 trial (AAIC 2024 poster
- 03Digital twins as a new lens for interpreting biomarker trends (AD/PD Vienna 2025 presentation
- 04Accelerated Alzheimer's trials using generative ML disease-progression forecasts (AAIC 2024 poster
- 05Evaluated digital-twins methodology using completed Alzheimer's Phase 2 data (AAIC 2022 presentation
- 06Used digital twins in a Phase 2a trial to predict Alzheimer's progression (AD/PD Boston 2025